Szpital Skawina Sp. z o.o.
- Address
- Ul. Tyniecka 15, 32-050 Skawina, Poland
Szpital Skawina Sp. z o.o. - Short Bowel Syndrome Research Center
Szpital Skawina Sp. z o.o. has established itself as a specialized center for research in short bowel syndrome (SBS), a rare and complex gastrointestinal disorder. The center focuses on evaluating innovative therapeutic approaches for patients with intestinal failure, particularly those requiring parenteral support due to insufficient intestinal absorption.
- Long-term safety and tolerability evaluation of novel GLP-2 analog therapies including apraglutide
- Clinical assessment of glepaglutide treatment in short bowel syndrome patients
- Advanced research in parenteral support reduction strategies for intestinal failure
The research center participates in multiple phases of clinical investigation, with particular emphasis on long-term safety monitoring and efficacy evaluation of emerging pharmaceutical interventions. Through participation in the EASE SBS clinical trial program, the facility contributes valuable data on treatment outcomes for this challenging patient population, helping to advance therapeutic options for individuals living with short bowel syndrome and intestinal failure.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Zealand Pharma A/S1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Zealand Pharma A/S4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Skawina Sp. z o.o.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials | Zealand Pharma A/S | Phase III | Not Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Glepaglutide | 4 | Unknown | 2019-04-30 | 2026-01-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.